Want to join the conversation?
$PFE 2Q15 Q&A: Gilbert of Deutsche Bank asked about the immune-oncology franchise. Ian replied that the company will be first in some tumor types with the PDL1 from Merck and will be well positioned with multiple combinations of immune-oncology assets and combinations of its own in-line assets to be very effective in those combinations.
Does anyone feel $SBUX CEO Schultz stepping down could prove a disaster for the company?
$DB is going to cut off services for about 3,400 clients in equities trading.
$F stock slid more than 2% after the company issued two safety recalls involving more than 650,000 Ford Fusion and Lincoln MKZ model cars.
The new CEO of $SBUX, Kevin Johnson, has some pretty large shoes to fill but there are many who have good faith in his ability to do so.